A $2.3 million National Cancer Institute grant will fund a University of Cincinnati Cancer Center study to develop a new technique to visualize where genetically modified immune cells go in the body after being administered to patients with cancer.

Recent research confirms that the gut microbiome plays a causal role in various chronic diseases, including infections, cancer, and inflammatory disorders, highlighting its potential as a therapeutic target. This review synthesizes evidence from randomized controlled trials, showing how microbiome therapies such as fecal microbiota transplantation (FMT) can reduce infection recurrence, improve immunotherapy response, and support remission in inflammatory conditions. The findings emphasize the microbiome’s promising role in future, non-invasive treatments for chronic disease management.

A novel test developed by Duke-NUS researchers enables real-time monitoring of T cells that have been engineered to fight cancer, after re-introduction into the body of a cancer patient. This simple and innovative test provides clinicians with the ability to track the function of these cancer-fighting cells over the course of the treatment. 

A novel test developed by Duke-NUS researchers enables real-time monitoring of T cells that have been engineered to fight cancer, after re-introduction into the body of a cancer patient. This simple and innovative test provides clinicians with the ability to track the function of these cancer-fighting cells over the course of the treatment.